Increase in Chronic Digestive Disorders Seen During Pandemic
WEDNESDAY, July 9, 2025 -- There was an increase in disorders of gut-brain interaction (DGBI) during the COVID-19 pandemic for those living in the United States, according to a study recently published online in Neurogastroenterology & Motility.
Christopher V. Almario, M.D., from Cedars-Sinai in Los Angeles, and colleagues assessed trends in the prevalence of Rome IV gastroduodenal and bowel DGBI over time based on survey responses from a nationally representative sample of more than 160,000 U.S. adults.
The researchers found that during the COVID-19 pandemic, the prevalence of irritable bowel syndrome (IBS) increased (6.1 [May 2020] to 11.0 percent [May 2022]; +0.188 percent/month), as did chronic idiopathic constipation (6.0 [May 2020] to 6.4 percent [May 2022]; +0.056 percent/month). The largest prevalence increase was seen in mixed IBS (+0.085 percent/month), IBS with constipation (+0.041 percent/month), and IBS with diarrhea (+0.037 percent/month). For the other examined gastroduodenal and bowel DGBI, there were no changes in prevalence.
"These findings underscore the significant toll the pandemic has taken on digestive health," Almario said in a statement. "These disorders involve chronic gastrointestinal symptoms that are often triggered or worsened by psychological stress."
Several authors disclosed ties to relevant organizations.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Further Support and Information on COVID-19
Read this next
Dementia Odds Significantly Increase With More Psychiatric Comorbidities
WEDNESDAY, Sept. 10, 2025 -- Dementia odds significantly increase with the number of psychiatric comorbidities, according to a study published online Sept. 9 in BMJ Mental...
Single Psychedelic Dose Reduces Symptoms of Generalized Anxiety Disorder
WEDNESDAY, Sept. 10, 2025 -- A single dose of a pharmaceutical formulation of LSD provides significant relief for patients with moderate-to-severe generalized anxiety disorder...
AI Performs Well for Endoscopic Assessment of Crohn Disease
TUESDAY, Sept. 9, 2025 -- Artificial intelligence shows good performance for automating ulceration and mucosal injury quantitation with Crohn disease, according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.